Royalty Pharma PLC
RPRX.O- Latest Trade
- trading lower38.71USD
- -0.01
- 0.03%
- As of Jan 26 2023. Values delayed up to 15 minutes
- Day Range
- 38.32 - 38.88
- 52-Week Range
- 36.15 - 44.75
- Previous Close
- 38.72
- Open
- 38.85
- Volume
- 1,432,876.00
- 3 Month Average Trading Volume
- 30.03
- Shares Out (Mil)
- 607.22
- Market Cap
- 23,232.31
- Forward P/E
- 10.44
- Dividend Yield
- 2.09
Key Statistics
1.90909091 mean rating - 11 analysts
- P/E Excl. Extra Items (TTM)
- 32.99
- Price To Sales (TTM)
- 10.34
- Price To Book (Quarterly)
- 3.78
- Price To Cash Flow (Per Share TTM)
- 25.66
- Total Debt/Total Equity (Quarterly)
- 115.59
- Long Term Debt/Equity (Quarterly)
- 99.39
- Return On Investment (TTM)
- 7.10
- Return On Equity (TTM)
- 5.05
2021 (millions USD)
About Royalty Pharma PLC (RPRX.O)
Company Information
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.
Address
110 East 59th StreetNEW YORK, NY
10022
United States
Industry
Misc. Financial Services
Executive Leadership
- Pablo Legorreta
- Chairman of the Board, Chief Executive Officer
- Christopher D. Hite
- Vice Chairman of the Board, Executive Vice President
- Terrance Coyne
- Chief Financial Officer, Executive Vice President
- James F. Reddoch
- Executive Vice President, Chief Scientific Officer
- Art Mcgivern
- Executive Vice President - Investments, General Counsel
- George Lloyd
- Executive Vice President - Investments & Chief Legal Officer
- Marshall Urist
- Executive Vice President - Research and Investments
- Henry A. Fernandez
- Lead Independent Director
- M. Germano Giuliani
- Director
- Rory B. Riggs
- Director
- Bonnie L. Bassler
- Independent Director
- Errol B. De Souza
- Independent Director
- Catherine Engelbert
- Independent Director
- Ted Wendell Love
- Independent Director
- Gregory Norden
- Independent Director
Latest News
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,929.10 | -- |
| Copper | 790.00 | 0.48% |
| Brent Crude Oil | 87.47 | -- |
| CBOT Soybeans | 1,523.50 | -- |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,060.43 | 1.10% |
| Euro STOXX 50 | 4,173.98 | 0.62% |
| FTSE 100 | 7,761.11 | 0.21% |
| Nikkei 225 | 27,408.89 | 0.17% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes